Xamoterol monotherapy in heart failure. The European 'Corwin' Group.

The effect of xamoterol as sole therapy was investigated in randomized, double-blind, placebo-controlled studies involving 425 patients with mild to moderate heart failure. When compared with placebo, xamoterol produced improvements in exercise capacity, clinical signs, symptoms and quality of life with a low incidence of adverse experiences. Xamoterol is effective as monotherapy in heart failure.

Cardiovascular effects of topical beta-blockers during exercise.

In two different medical centers, a total of 24 normal individuals (mean age, 31 years) participated in a double-masked, three-way crossover single-instillation comparison of betaxolol 1%, timolol 0.5%, and placebo. After each ocular treatment, cardiovascular characteristics were measured during ten-minute treadmill exercise periods.

Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis.

The hydroxy metabolite of metronidazole was found to be more active against 21 strains of Gardnerella vaginalis than the parent compound and less affected by culture in carbon dioxide. After 400 mg oral metronidazole (Flagyl) plasma concentrations of the two agents were below the minimum inhibitory concentrations (MICs) for most G vaginalis strains tested. With 2 g metronidazole the plasma concentrations exceeded the MICs of the more sensitive strains.

Isoelectric focusing of Bacteroides melaninogenicus group beta-lactamases.

beta-Lactamases extracted by sonication from the Bacteroides melaninogenicus group organisms (B. asaccharolyticus, B. melaninogenicus, B.